Skip to main content
Premium Trial:

Request an Annual Quote

Proteome, Shimadzu to Launch Proteomics Facilities

NEW YORK, Dec 4 - Proteome Systems and Shimadzu said Monday they would jointly establish proteomics facilities in Sydney, Australia, and Boston, extending an alliance they originally formed earlier this year.

The companies’ joint proteomics efforts will rely on advanced sample preparation technologies and chemical printers that have been jointly developed by Proteome Systems and Shimadzu. These will be interfaced with AXIMA MALDI-TOF mass spectrometers, manufactured by Shimadzu’s Kratos Analytical subsidiary.

Shimadzu is also planning to implement the proteomics platform within its Kyoto facilities in 2001.

Under the terms of the partnership, Shimadzu and Proteome Systems will jointly develop new proteomics tools that will help to automate protein analysis. The companies said they expect to launch their first system around August 2001.

The companies are also considering incorporating Proteome Systems’ Glycosite analysis tools into the proteomics tools Shimadzu is developing.

“The goal is to develop an integrated platform of instruments for high level protein and glycoprotein characterization,” Proteome Systems said in a statement.

Neither company was immediately available for comment.

Shimadzu, a 125-year-old Japanese firm, manufactures scientific instruments. It recently released a high-throughput DNA sequencer as part of its efforts to establish a foothold in the genomics sector.

Proteome Systems of Australia develops high-throughput proteomics platforms and develops bioinformatics tools for proteomics. The company has more than 60 employees in Sydney and Boston.
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.